Cel Sci Corporation (CVM)

[GD]

W-W, You are 100% correct, It is that simple, all the data are numbers,
CRO just has to define the conditions and run through the data base,
come out all the tables like Sushi give the example in the Dropbox,
the primary endpoint and secondary endpoints are pre-defined in SAP
approved by FDA, rest of the subgroup data are defined by mostly enrollment
Inclusion Criteria, that is all, nothing complicated. IMO, NWBO data
are muddy, NWBO's new primary OS endpoint may be weak positive
like P 0.04-0.05, but 3 or 4 of the secondary are not SS, and that is
why NWBO is holding the TLD, trying to find a way to present them
a positive way, but The best writing skills or a perfect presentation cannot
compensate for a trial with weak data set! If MK has strong efficacy,
the full data set is clean on all points, take look at the primary OS endpoint
KM curves in Sushi's dropbox presentation, what a beautiful picture,
separate early and consistent gap to the end that produce a low P
value 0.002, if MK trial produces the OS KM curves like that one,
HR 0.74 P value 0.002, CVM hits the jackpot, homerun results, and
CVM stock tests 100 on the first day after the PR, IMO.